Advertisement
Advertisement
ASND
Ascendis Pharma A/S Ordinary Share
230.70
USDSponsored
+7.57
+3.39%
Sep 24, 15:59 UTC -4
Closed
Pre-Market
231.69
+1.00
+0.43%
ASND Earnings Reports
Positive Surprise Ratio
ASND beat 16 of 43 last estimates.
37%
Next Report
Date of Next Report
Nov 09, 2026
Estimate for Q3 26 (Revenue/ EPS)
$371.80M
/$0.94
Implied change from Q2 26 (Revenue/ EPS)
+9.58%
/+30.56%
Implied change from Q3 25 (Revenue/ EPS)
+74.03%
/-194.00%
Ascendis Pharma A/S Ordinary Share earnings per share and revenue
On Aug 13, 2026, ASND reported earnings of 0.72 USD per share (EPS) for Q2 26, missing the estimate of 1.40 USD, resulting in a -48.88% surprise. Revenue reached 339.29 million, compared to an expected 338.19 million, with a 0.32% difference. The market reacted with a +2.31% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 12 analysts forecast an EPS of 0.94 USD, with revenue projected to reach 371.80 million USD, implying an increase of 30.56% EPS, and increase of 9.58% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Abivax SA - ADR
Report Date
Sep 21, 2026 For Q2 26
Estimate
-$1.82
Actual
-$2.09
Surprise
-14.47%
AnaptysBio, Inc. Common Stock
Report Date
Sep 21, 2026 For Q2 26
Estimate
$0.00
Actual
$5.11
Surprise
>+10,000.00%
BlossomHill Therapeutics, Inc. Common Stock
Report Date
Sep 18, 2026 For Q2 26
Estimate
-$1.03
Actual
-$8.75
Surprise
-746.56%
Vogenx Inc Common Stock
Report Date
Sep 17, 2026 For Q2 26
Estimate
-$0.07
Actual
-$0.07
Surprise
+1.96%
Benitec Biopharma Inc. Common Stock
Report Date
Sep 14, 2026 For Q4 26
Estimate
-$0.27
Actual
-$0.26
Surprise
+5.59%
AYTU BioPharma, Inc. Common Stock
Report Date
Sep 22, 2026 For Q4 26
Estimate
-$0.33
Actual
-$0.05
Surprise
+84.92%
Neuphoria Therapeutics Inc. Common Stock
Report Date
Sep 18, 2026 For Q4 26
Estimate
-$0.57
Actual
-$0.95
Surprise
-66.32%
NewcelX Ltd. Ordinary Shares
Report Date
Sep 18, 2026 For Q2 26
Estimate
-$0.54
Actual
-$0.96
Surprise
-77.58%
FAQ
What were Ascendis Pharma A/S Ordinary Share's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Ascendis Pharma A/S Ordinary Share reported EPS of $0.72, missing estimates by -48.88%, and revenue of $339.29M, 0.32% above expectations.
How did the market react to Ascendis Pharma A/S Ordinary Share's Q2 2026 earnings?
The stock price moved up 2.31%, changed from $244.20 before the earnings release to $249.85 the day after.
When is Ascendis Pharma A/S Ordinary Share expected to report next?
The next earning report is scheduled for Nov 09, 2026.
What are the forecasts for Ascendis Pharma A/S Ordinary Share's next earnings report?
Based on 12
analysts, Ascendis Pharma A/S Ordinary Share is expected to report EPS of $0.94 and revenue of $371.80M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.